Literature DB >> 18625408

Genetics of amyotrophic lateral sclerosis.

Nailah Siddique1, Teepu Siddique.   

Abstract

Amyotrophic lateral sclerosis (ALS) was first described by Charcot in 1869 as what we would now call a sporadic disease-a disease believed to occur without a strong genetic influence. Only within the past 10 years has it been possible to fully explore genetic influence on disorders that seem to occur sporadically but likely result from the convergence of multiple genetic and environmental factors. This article reviews the genetics of familial ALS and summarizes current investigations of genetic influence in sporadic ALS. Genetic study clearly offers the potential for identification of molecular targets that would allow development of rational therapies for various forms of ALS, but much work remains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625408      PMCID: PMC2553626          DOI: 10.1016/j.pmr.2008.05.001

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  39 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis.

Authors:  M E Cudkowicz; D McKenna-Yasek; P E Sapp; W Chin; B Geller; D L Hayden; D A Schoenfeld; B A Hosler; H R Horvitz; R H Brown
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

3.  Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers.

Authors:  A Hentati; K Ouahchi; M A Pericak-Vance; D Nijhawan; A Ahmad; Y Yang; J Rimmler; W Hung; B Schlotter; A Ahmed; M Ben Hamida; F Hentati; T Siddique
Journal:  Neurogenetics       Date:  1998-12       Impact factor: 2.660

4.  Mutant SOD1 causes motor neuron disease independent of copper chaperone-mediated copper loading.

Authors:  Jamuna R Subramaniam; W Ernest Lyons; Jian Liu; Thomas B Bartnikas; Jeffrey Rothstein; Donald L Price; Don W Cleveland; Jonathan D Gitlin; Philip C Wong
Journal:  Nat Neurosci       Date:  2002-04       Impact factor: 24.884

5.  The D90A mutation results in a polymorphism of Cu,Zn superoxide dismutase that is prevalent in northern Sweden and Finland.

Authors:  A Själander; G Beckman; H X Deng; Z Iqbal; J A Tainer; T Siddique
Journal:  Hum Mol Genet       Date:  1995-06       Impact factor: 6.150

6.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen
Journal:  Nature       Date:  1993-07-22       Impact factor: 49.962

7.  Prognosis in familial amyotrophic lateral sclerosis: progression and survival in patients with glu100gly and ala4val mutations in Cu,Zn superoxide dismutase.

Authors:  T Juneja; M A Pericak-Vance; N G Laing; S Dave; T Siddique
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

8.  The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis.

Authors:  Y Yang; A Hentati; H X Deng; O Dabbagh; T Sasaki; M Hirano; W Y Hung; K Ouahchi; J Yan; A C Azim; N Cole; G Gascon; A Yagmour; M Ben-Hamida; M Pericak-Vance; F Hentati; T Siddique
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

9.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

Authors:  M E Gurney; H Pu; A Y Chiu; M C Dal Canto; C Y Polchow; D D Alexander; J Caliendo; A Hentati; Y W Kwon; H X Deng
Journal:  Science       Date:  1994-06-17       Impact factor: 47.728

10.  Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase.

Authors:  H X Deng; A Hentati; J A Tainer; Z Iqbal; A Cayabyab; W Y Hung; E D Getzoff; P Hu; B Herzfeldt; R P Roos
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

View more
  7 in total

1.  The preclinical discovery of amyotrophic lateral sclerosis drugs.

Authors:  Marcie A Glicksman
Journal:  Expert Opin Drug Discov       Date:  2011-10-25       Impact factor: 6.098

2.  Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model.

Authors:  Diana García Del Barco; Héctor Pérez-Saad; Valia Rodríguez; Javier Marín; Viviana Falcón; Jorge Martín; Danay Cibrian; Jorge Berlanga
Journal:  Neurotox Res       Date:  2010-02-19       Impact factor: 3.911

Review 3.  Glycoproteomics in neurodegenerative diseases.

Authors:  Hyejin Hwang; Jianpeng Zhang; Kathryn A Chung; James B Leverenz; Cyrus P Zabetian; Elaine R Peskind; Joseph Jankovic; Zhen Su; Aneeka M Hancock; Catherine Pan; Thomas J Montine; Sheng Pan; John Nutt; Roger Albin; Marla Gearing; Richard P Beyer; Min Shi; Jing Zhang
Journal:  Mass Spectrom Rev       Date:  2010 Jan-Feb       Impact factor: 10.946

4.  Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice.

Authors:  Ana C Calvo; Raquel Manzano; Gabriela Atencia-Cibreiro; Sara Oliván; María J Muñoz; Pilar Zaragoza; Pilar Cordero-Vázquez; Jesús Esteban-Pérez; Alberto García-Redondo; Rosario Osta
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

5.  Structural and functional analysis of human SOD1 in amyotrophic lateral sclerosis.

Authors:  Lorenna Giannini Alves Moreira; Livia Costa Pereira; Priscila Ramalho Drummond; Joelma Freire De Mesquita
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

6.  Searching the overlap between network modules with specific betweeness (S2B) and its application to cross-disease analysis.

Authors:  Marina L Garcia-Vaquero; Margarida Gama-Carvalho; Javier De Las Rivas; Francisco R Pinto
Journal:  Sci Rep       Date:  2018-08-01       Impact factor: 4.379

7.  Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).

Authors:  Laura E Cox; Laura Ferraiuolo; Emily F Goodall; Paul R Heath; Adrian Higginbottom; Heather Mortiboys; Hannah C Hollinger; Judith A Hartley; Alice Brockington; Christine E Burness; Karen E Morrison; Stephen B Wharton; Andrew J Grierson; Paul G Ince; Janine Kirby; Pamela J Shaw
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.